Dr. Stein on Commercial Tests to Determine Therapies for Prostate Cancer | OncLive

Dr. Stein on Commercial Tests to Determine Therapies for Prostate Cancer

January 19, 2017

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses commercial tests for determining therapies for patients with prostate cancer.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses commercial tests for determining therapies for patients with prostate cancer.

Certain tests are helpful when understanding some of the more challenging clinical situations, explains Stein. It is not something that is routinely done, due to different insurance funds. However, it is effective during certain cases, in regards to determining which therapy a patient should receive.

Technology and platforms are developing quickly, making it necessary for physicians to remain updated on the ongoing trials in order to decide the most beneficial treatment for a patient. For instance, explains Stein, there might be trials looking at a particular biomarker, which could be an important way to determine which trials to enroll patients on.


x